` GNTA (Genenta Science SPA) vs S&P 500 Comparison - Alpha Spread

GNTA
vs
S&P 500

Over the past 12 months, GNTA has underperformed S&P 500, delivering a return of -17% compared to the S&P 500's +15% growth.

Stocks Performance
GNTA vs S&P 500

Loading
GNTA
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
GNTA vs S&P 500

Loading
GNTA
S&P 500
Difference
www.alphaspread.com

Performance By Year
GNTA vs S&P 500

Loading
GNTA
S&P 500
Add Stock

Competitors Performance
Genenta Science SPA vs Peers

S&P 500
GNTA
ABBV
AMGN
GILD
VRTX
Add Stock

Genenta Science SPA
Glance View

Market Cap
64.1m USD
Industry
Biotechnology

Genenta Science SpA engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. The company is headquartered in Milan, Milano and currently employs 4 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.

GNTA Intrinsic Value
0.8105 USD
Overvaluation 77%
Intrinsic Value
Price
Back to Top